GoKawiilRegenerative-medicine trials underrepresent women and exclude non-binary participants, study finds
An analysis by researchers including the article's author found that women make up around 41% of participants in cardiovascular disease clinical trials generally, but only 18-20% in regenerative-medicine trials for the same condition. Self-identified non-binary people were largely absent from these studies, according to the 2021 analysis.
GoKawiil's interpretation of the reporting above, not reported fact.
The author argues that this gap could mean research findings fail to apply equally across sexes, potentially causing women and non-binary people to miss out on effective therapies while safety risks go undetected once treatments reach wider clinical use. The piece suggests structural fixes—better recruitment, retention and sex-based reporting, plus more diverse investigators—could address the imbalance, though these remain proposed solutions rather than confirmed outcomes.
- Women comprise just 18-20% of participants in cardiovascular regenerative-medicine trials, versus 41% in CVD trials overall
- Non-binary individuals are largely missing from these clinical studies
- Researchers call for intentional recruitment, retention strategies and sex-based data reporting to close the gap
Source: nature.com — Taylor, 2026-09-23
Published there as: “Lack of female researchers and participants in regenerative-medicine research holds everyone back”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.